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Heterogeneity in Center Practices in Liver
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INTRODUCTION: Alcohol-related liver disease (ALD) is now the leading indication for liver transplantation (LT) in the

United States (US). It remains unclear how centers are managing the medical and psychosocial issues
associated with these patients.
METHODS:

We conducted a web-based survey of LT centers in the United States to identify center-level details on
peri-LT management of ALD and related issues.

RESULTS:

Of the 117 adult LT centers, 100 responses (85.5%) were collected, representing all Organ
Procurement and Transplantation Network regions. For alcohol-associated cirrhosis, 70.0% of the
centers reported no minimum sobriety requirement while 21.0% required 6 months of sobriety. LT for
severe alcohol-associated hepatitis was performed at 85.0% of the centers. Monitoring protocols for
pre-LT and post-LT alcohol use varied among centers.

DISCUSSION:

Our findings highlight a change in center attitudes toward LT for ALD, particularly for severe alcoholassociated hepatitis.

SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/AJG/C547, http://links.lww.com/AJG/C548
Am J Gastroenterol 2022;117:1530–1535. https://doi.org/10.14309/ajg.0000000000001863

INTRODUCTION
Alcohol-associated liver disease (ALD) is now the leading indication for liver transplantation (LT) in the United States (US)
because of an increase in the prevalence of alcohol use disorder
(AUD), particularly among younger people and women (1–3).
Furthermore, demonstration of LT as a lifesaving therapy for
select candidates with alcohol-associated hepatitis (AAH) has
forced centers to re-evaluate previous attitudes and practices that
have restricted LT in this patient population (3–6). After LT,
relapse in alcohol use can have signiﬁcant long-term eﬀects on
both graft and patient survival (7, 8). Successful management of
AUD pre-LT and post-LT requires a multidisciplinary approach
including hepatologists, addiction specialists, social workers, and
psychiatrists (9).
With the increase in LT for ALD, it is not clear how centers are
managing the new burden of accompanying complex medical

and psychosocial issues to optimize clinical outcomes in their
patients. We conducted a national survey of LT centers to deﬁne
current center resources, practices, and protocols in the management of ALD before and after LT.

METHODS
We developed a survey (see Supplementary Material, Supplementary Digital Content 1, http://links.lww.com/AJG/C547)
using case-based and logic-based questions and disseminated
this survey using a national list of 117 adult LT medical directors from January 05, 2021, to March 08, 2021. No incentives
were provided for completion of the survey. The survey was
deemed exempt by the Institutional Review Board at the University of Minnesota. Further methods are described in the
supplemental material, Supplementary Digital Content 1,
http://links.lww.com/AJG/C547.
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Figure 1. Center resources for the management of alcohol use disorder.

RESULTS
Center characteristics and resources

There were 100 unique responses (85.5%) representing all 11 of
the Organ Procurement and Transplantation Network regions.
Responding center characteristics are presented in Supplementary Table 1, Supplementary Digital Content 2, http://links.lww.
com/AJG/C548. The availability of resources for the management
of AUD is described in Figure 1.
LT for alcohol-associated cirrhosis

Most of the responding centers (70.0%) reported no minimum
sobriety requirement for consideration of LT for alcoholassociated cirrhosis (AAC). Of the remaining 30 centers, 21
centers (70.0%) required a minimum sobriety time of 6
months and 9 (30.0%) required a minimum of 3 months
(Table 1).
Monitoring for alcohol use in patients with AAC

During the evaluation and listing periods, all centers used alcohol biomarkers to monitor sobriety in patients with AAC:
95.0% of the centers used serum phosphatidylethanol (PETH).
In the event of reported alcohol use or a positive alcohol biomarker, 74.0% of the centers used a protocol. In the post-LT
period, biomarkers were used by 79.0% of the centers to
monitor sobriety while PETH remained the most commonly
used assay. In the event of reported alcohol use or positive
© 2022 by The American College of Gastroenterology

biomarkers in the post-LT period, 46 centers (46.5%) reported
that they had a protocol. A visit with a transplant provider
(87%) and social worker (84.8%) was the most common
component.
LT for severe AAH

Regarding severe AAH, 85 centers (85.0%) reported performing LT, most of whom (75.3%) started this practice within
the past 5 years. Seventy-four centers (87.1%) reported using
an institution-speciﬁc protocol with a high degree of similarity
in protocol components between centers (Figure 2).
For relapse risk stratiﬁcation, the Stanford Integrated Psychosocial Assessment for Transplant score was used in 45
centers (60.8%) (Table 2). Approximately 70% of the centers
reported inclusion of a patient contract or agreement, and 62
centers (83.8%) scheduled or arranged a treatment plan for
AUD before LT. Deﬁned metrics for success in patients undergoing LT for severe AAH were used in 29 centers (39.2%). In
the post-LT period, 74 centers (87.1%) reported using alcohol
biomarkers to monitor sobriety from alcohol, again with a near
uniform use of serum PETH (95.9%). Forty-three of the 74
centers (58.1%) had a speciﬁc protocol for monitoring alcohol
use, the majority on a monthly basis. Forty of the 85 centers
(47.1%) performing LT for severe AAH reported having a
protocol in the event of reported alcohol use or positive alcohol
biomarkers.
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Table 1. LT for alcohol-associated cirrhosis
Does your center have a minimum sobriety
requirement for alcohol-associated cirrhosis?
Yes

Table 1. (continued)
%

Every 6 mo

2 (2.5)

Other

6 (7.6)

30.0
Not checked routinely

Does your center have a minimum sobriety
requirement before evaluation/listing for LT?
Yes

24 (30.4)

N (%)
Does your center have a protocol in the event
of alcohol use?
30 (30.0)
Yes

What is the duration of minimum sobriety
required at your center?
3 mo
6 mo
Pre-LT monitoring for sobriety

Protocol components
9 (30.0)
21 (70.0)
N (%)
90 (90.0)

Direct interviewing

91 (91.0)

External report

85 (85.0)

95 (95.0)

Urine ethyl glucuronide

61 (61.0)

Serum gamma-glutamyltransferase

3 (3.0)
19 (19.0)

Monthly

46 (46.9)

3-Monthly

21 (21.4)

6-Monthly
Not checked routinely
Does your center have a protocol in the event
of alcohol use?
Yes
Protocol components
Evaluation or listing placed on hold

1 (1.0)
24 (24.5)
N (%)
73 (73.7)
N (%)
59 (80.8)

Patient is delisted

33 (45.2)

Chemical dependency evaluation

33 (45.2)

Transplant provider visit

51 (69.9)

Mental health/Addiction medicine
provider visit

43 (58.9)

Social work visit

57 (78.1)

Post-LT monitoring for sobriety

N (%)

Self-report

86 (86.0)

Direct interviewing

82 (82.0)

External report

70 (70.0)

Alcohol biomarkers

79 (79.0)

Serum phosphatidylethanol

74 (93.7)

Urine ethyl glucuronide

39 (49.4)

Serum carbohydrate-deficient transferrin
Serum gamma-glutamyltransferase

1 (1.3)
11 (13.9)

Frequency
Monthly

27 (34.2)

Every 3 mo

20 (25.3)
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N (%)

Chemical dependency evaluation

30 (65.2)

Transplant provider visit

40 (86.9)

Mental health/addiction medicine provider
visit

35 (76.1)

Social work visit

39 (84.8)

LT, liver transplantation.

100 (100.0)

Serum phosphatidylethanol

Serum carbohydrate-deficient transferrin

46 (46.5)

N (%)

Self-report

Alcohol biomarkers

N (%)

Subgroup analysis by practice type, center volume, and MMaT

No diﬀerences were observed when subgroup analyses were
performed according to center type (university-based versus nonuniversity-based), center volume (1–50, 51–100, and .100), and
center MMaT (#26, 27–29, and $30). (see Supplemental Tables
2 to 4, Supplementary Digital Content 2, http://links.lww.com/
AJG/C548).

DISCUSSION
We report the ﬁndings from a national survey of LT centers on
practices and the use of protocols in patients who undergo LT for
ALD. Notably, most of the centers are now engaging in LT for
severe AAH. Furthermore, our results underscore the heterogeneity across centers when considering resources and practices in
the care of patients with ALD.
In response to the clinical scenario involving AAC, our results
show that most of the LT programs no longer impose a mandatory sobriety requirement in the evaluation process for patients
with ALD. A recent study showed no diﬀerence in clinical outcomes between patients undergoing LT with less than 6 months of
sobriety from alcohol and those with at least 6 months sobriety
(10). LT centers seem to have embraced both the complexity of
AUD as a disease entity and the fact that the risk of alcohol relapse
after LT cannot be distilled into a simple time frame.
Similarly, most US LT programs are oﬀering LT for severe
AAH today in contrast with 47 in 2019 (11). This is likely because
of the growing body of evidence describing excellent short-term
outcomes in patients undergoing early LT for severe AAH (4–6).
Most of the centers reported using a protocol: Adequate caregiver
support and insight into diagnosis of AUD were the most frequent components of these protocols, aligning with recommendations from the recent Dallas Consensus Conference on LT for
AAH (12). Despite such protocols, most centers did not have a
deﬁned metric of success for LT in AAH and for those who did,
there was a lack of consensus indicating that guidance on the
metrics of success after LT for ALD is much needed and will likely
need to incorporate program and patient priorities (13).
Our results also show the prominent role of alcohol biomarkers in both pre-LT and post-LT monitoring for alcohol use
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Figure 2. Center protocols for the evaluation and listing of patients with severe alcohol-associated hepatitis. AUD, alcohol use disorder.

in patients with ALD. Serum PETH, a highly speciﬁc and sensitive
marker of alcohol use, was almost ubiquitous for monitoring for
alcohol use before and after LT for all types of ALD (14, 15).
A protocolized use of alcohol biomarkers can facilitate the detection of slips in alcohol use to provide a critical opportunity for
intervention before they develop into full relapses and aﬀect
clinical outcomes (7, 8).
We observed a concerning drop-oﬀ in protocol-based routine
monitoring between the pre-LT and post-LT settings. In addition,
visits with transplant providers were featured prominently in
protocols for the management of recurrent alcohol use in our
survey. With a recent survey reporting that gastroenterology and
hepatology providers often do not feel comfortable prescribing
medications for the management of AUD, our data raise questions of whether transplant providers are adequately trained to
manage the needs of this growing patient population (16).
There was signiﬁcant heterogeneity across LT centers regarding access to resources for the management of AUD. Many
centers did not have access to a transplant psychiatrist or addiction medicine specialist as part of their LT program. Integration of psychiatry and addiction services into LT clinics has
been shown to reduce costs and improve clinical outcomes
(17–20). Because the incidence of ALD continues to increase, LT
centers will need to ensure that they are adequately resourced to
care for the lifelong needs of these patients.
© 2022 by The American College of Gastroenterology

The strengths of this survey include the high response rate of
85.5%, which ensures that our ﬁndings are representative of the
US LT community. We chose to evaluate practices and protocols
at a center level to minimize any biases and variability that may
arise from sampling individual providers. The survey design did
not allow us to explore possible reasons for the heterogeneity in
resources and protocols for ALD management, which needs
further study.
In summary, as the burden of ALD increases across the United
States, most LT centers no longer require a minimum sobriety
requirement before pursuing LT, and most centers are now performing LT for severe AAH. The results of our survey underscore
the need for greater standardization of care to improve clinical
outcomes in patients with ALD. Further work should explore the
quality of currently used ALD protocols and interview-based
studies to investigate sources of heterogeneity in LT practices.
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Table 2. LT for severe AAH
Does your center perform LT for severe AAH?
Yes
No. of years performing LT for severe AAH

Table 2. (continued)
%
85.0
%

0–5 yr

75.3

51 yr

24.7

No. of patients evaluated for LT for severe AAH per year

n (%)

0–5 patients

3.5

6–10 patients

24.7

11–20 patients

31.8

201 patients

40.0

No. of patients transplanted for LT for severe AAH
per year

n (%)

Every 3 mo

9 (17.3)

Every 6 mo

12 (23.1)

Annually

22 (42.3)

Other

7 (13.5)

Post-LT monitoring for sobriety

75 (88.2)

Direct interviewing

73 (85.9)

External report

66 (77.6)

Alcohol biomarkers

74 (87.1)

Serum phosphatidylethanol

71 (95.9)

Urine ethyl glucuronide

41 (55.4)

Serum carbohydrate-deficient transferrin
0–5 patients

51 (60.0)

6–10 patients

15 (17.7)

Serum gamma-glutamyltransferase
111 patients
Does your center have a protocol for evaluation and
transplantation of patients with severe AAH?

19 (22.4)
n (%)

n (%)

Self-report

Does your center check alcohol biomarkers routinely
after LT for severe AAH?
Yes

1 (1.4)
13 (17.6)
n (%)
43 (58.1)

Frequency
Yes
How long has your center been using a protocol?
0–1 yr

74 (87.1)
25 (58.1)

Every 3 mo

10 (23.3)

Every 6 mo

1 (2.3)

16 (21.6)

2-4 yr

42 (56.8)

51 yr

16 (21.7)

Which scoring systems are incorporated into your
center protocol?

Monthly
n (%)

Annually

1 (2.3)

Other

6 (13.9)

n (%)
Does your center have a protocol in the event of
alcohol use?

SALT

26 (35.1)

SIPAT

45 (60.8)

Other

18 (24.4)

Yes

40 (47.1)

Protocol components

n (%)

Chemical dependency evaluation
None
Does your center protocol include a patient contract/
agreement?
Yes
Is a treatment plan for AUD arranged before LT?
Yes
Does your center’s protocol have a defined metric for
“success” in patients undergoing LT for severe AAH?
Yes
What metric does your center define as “success” in
these patients?

52 (70.3)
n (%)
62 (83.8)

n (%)

Graft survival

22 (75.9)

Patient survival

22 (75.9)

The American Journal of GASTROENTEROLOGY

31 (77.5)

Social work visit

35 (87.5)

AAH, alcohol-associated hepatitis; AUD, alcohol use disorder; LT, liver
transplantation; SALT, Sustained Alcohol use post-Liver Transplant; SIPAT,
Stanford Integrated Psychosocial Assessment for Transplant.

29 (39.2)

20 (68.9)

Monthly

36 (90.0)

Mental health/Addiction medicine provider visit

n (%)

16 (55.2)

How often does your center audit this protocol?

Transplant provider visit
n (%)

Starting treatment for AUD

Yes

24 (60.0)

12 (16.2)

Absolute sobriety

Does your center audit your protocol for LT for patients
with severe AAH?

n (%)

n (%)
52 (70.3)
n (%)
2 (3.9)
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